These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 10442372)
21. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy]. Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684 [TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Kasumi F; Yoshimoto M; Uchino J; Abe R; Nomura Y; Sugimachi K; Nakazato H; Abe O Oncology; 2003; 64(2):146-53. PubMed ID: 12566912 [TBL] [Abstract][Full Text] [Related]
23. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R; Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868 [TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
25. Appraisal of adjuvant chemoendocrine therapy with tamoxifen plus tegafur in patients with breast cancer. Enomoto K; Fujiwara K; Ikeda T; Katoh S; Abe O Keio J Med; 1991 Sep; 40(3):123-8. PubMed ID: 1753554 [TBL] [Abstract][Full Text] [Related]
26. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766 [TBL] [Abstract][Full Text] [Related]
27. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417 [TBL] [Abstract][Full Text] [Related]
28. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Toi M; Hattori T; Akagi M; Inokuchi K; Orita K; Sugimachi K; Dohi K; Nomura Y; Monden Y; Hamada Y Cancer; 1992 Nov; 70(10):2475-83. PubMed ID: 1423177 [TBL] [Abstract][Full Text] [Related]
29. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial]. Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855 [TBL] [Abstract][Full Text] [Related]
30. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Hillner BE Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322 [TBL] [Abstract][Full Text] [Related]
31. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. Pohl G; Rudas M; Dietze O; Lax S; Markis E; Pirker R; Zielinski CC; Hausmaninger H; Kubista E; Samonigg H; Jakesz R; Filipits M J Clin Oncol; 2003 Oct; 21(19):3594-600. PubMed ID: 14512390 [TBL] [Abstract][Full Text] [Related]
32. Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up. Marshall JS; Gordon NH; Hubay CA; Pearson OH J Lab Clin Med; 1987 Mar; 109(3):300-7. PubMed ID: 3819572 [TBL] [Abstract][Full Text] [Related]
33. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805 [TBL] [Abstract][Full Text] [Related]
34. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276 [TBL] [Abstract][Full Text] [Related]
35. Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer. Fujii M Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):55-60. PubMed ID: 10442363 [TBL] [Abstract][Full Text] [Related]
36. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725 [TBL] [Abstract][Full Text] [Related]
37. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202 [TBL] [Abstract][Full Text] [Related]
38. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529 [TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B; Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287 [TBL] [Abstract][Full Text] [Related]
40. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group. Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]